Vancouver, Washington-based CytoDyn filed a second clinical trial protocol with the U.S. Food and Drug Administration to treat severely sick COVID-19 patients.
Johnson & Johnson is moving forward with a vaccine candidate for COVID-19, with human testing starting during September and the first batches available under potential emergency use authorization expected in the first part of 2021.
Abbott Laboratories won U.S. marketing approval for a diagnostic test for the coronavirus that can deliver results to patients within minutes and be used in physicians’ offices and urgent care clinics, as well as hospitals.
Sanofi and Regeneron Pharmaceuticals expanded a clinical trial of the companies’ rheumatoid arthritis drug Kevzara as a coronavirus treatment to patients outside the United States.
A day after the announcement that remdesivir received Orphan Drug designation for the treatment of COVID-19 from the U.S. Food and Drug Administration, Gilead Sciences submitted a request for the regulatory agency to rescind that offer after an outcry was raised over the potential for exclusivity for the experimental pandemic treatment.
Gilead Sciences has been overwhelmed with requests for remdesivir to treat cases of COVID-19, the disease caused by the novel coronavirus.
A lot of attention shifted to the malaria drug hydroxychloroquine for treatment of COVID-19, the disease caused by the novel coronavirus.
Roche Holding AG Chief Executive Officer Severin Schwan said in an interview with CNBC it could take at least a couple of weeks, if not months, for the United States to implement broad testing for coronavirus.
As the number of diagnosed cases of COVID-19 continues to rise in the United States, Eli Lilly partnered with the Indiana State Department of Health to accelerate testing for the virus in that state.
A Biogen employee with symptoms of the novel coronavirus COVID-19 was terminated by the company after she left her home in Massachusetts and boarded a plane to China without disclosing her exposure to the virus.
